Last reviewed · How we verify
Anti-PD1 (anti-pd1)
Anti-PD1 PF-06801591
Anti-PD1 is an immunotherapy that blocks the PD1 checkpoint inhibitor pathway to reinvigorate exhausted T cells and restore anti-tumor immunity. It is approved for various solid and hematologic malignancies where it has demonstrated improved survival outcomes. Key differentiator: enables the immune system to recognize and attack cancer cells that would otherwise evade detection.
At a glance
| Generic name | anti-pd1 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Anti-PD1 PF-06801591 |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Cancer cells have developed a clever trick to hide from your immune system. They display a protein called PD-L1 on their surface that binds to a receptor called PD1 on immune cells, sending a signal that essentially tells these immune cells to stand down and stop fighting. This is like cancer putting up a 'do not disturb' sign that your body's defenders respect. Anti-PD1 drugs work by blocking this interaction. They act as a shield that covers the PD1 receptor on immune cells, preventing cancer's PD-L1 signal from getting through. With this communication channel blocked, the immune cells no longer receive the 'stop fighting' message and instead resume their attack on cancer cells. It's essentially removing the muzzle from your immune system and unleashing it to do its job. Once freed from this suppression, your T cells can recognize, multiply, and destroy cancer cells throughout the body. This approach has proven effective across multiple cancer types because it works with your body's natural defense mechanisms rather than introducing foreign substances, though it can sometimes lead to immune-related side effects as the newly activated immune system may also attack healthy tissue.
Approved indications
Pipeline indications
- Gastrointestinal Tumors — discontinued
Common side effects
Key clinical trials
- A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumo (Phase 1)
- A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Can (Phase 1/2)
- Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metas (Phase 1)
- An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lun (Phase 2)
- GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors (Phase 1)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer The (Phase 1)
- A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Par (Phase 3)
- Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors an (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-PD1 CI brief — competitive landscape report
- Anti-PD1 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI